The cell and gene therapy sector continues to face significant headwinds in 2025, as investors increasingly favor lower-risk investments over the more complex cell and gene therapy spaces. Explore the state of the market and the road ahead in this Trendline.
|
Access now for stories such as:
|
-
Sana to lay off staff, deepen autoimmune focus in latest retrenchment
-
As cell and gene therapy field pivots, investment hits a speed bump
-
4 tips for managing protocol deviations in cell therapy clinical trials
|
|
This Trendline is independently produced by our journalists. The support of our sponsors makes this journalism possible. Want to learn about sponsorship opportunities? Contact us directly at advertising@industrydive.com.
|
|
|
|
